FibroBiologics, Inc.
About FibroBiologics, Inc.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$18.6M
- Total assets
- $9.6M
- Market cap
- $5.4M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 31, 2024
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review FibroBiologics, Inc..
